BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New Generation Asthma Drug Could Improve Metabolism, Garvan Institute of Medical Research Research Suggests


6/6/2011 6:51:16 AM

Formoterol, a new generation asthma medication, shows great promise for improving fat and protein metabolism, say Australian researchers, who have tested this effect in a small sample of men. The researchers present their results today at The Endocrine Society’s 93rd Annual Meeting in Boston.

The research team comprises members of Professor Ken Ho’s lab from Sydney’s Garvan Institute of Medical Research as well as Professor Ric Day, a clinical pharmacologist from St. Vincent’s Hospital.

Study leader, endocrinologist Dr Paul Lee, focused his PhD research on how various hormones affect metabolism. Of central importance is a class of hormones called catecholamines, which regulate heart rate, metabolism and breathing.

Formoterol is a synthetic catecholamine, the metabolic effects of which have not previously been studied in people. Therapy doses given to animals, however, have shown that it stimulates metabolism without affecting the heart.

“We have known for a long time that catecholamine influences the way the body handles nutrients, in particular fat and protein,” said Lee.

“The generation of drugs before formoterol was exploited in the livestock industry around 20 years ago – to reduce the fat and increase the protein content of meat. Unfortunately, these older drugs also caused a faster heart rate.”

“Formoterol is a new generation of this class of medication. It is highly selective for the kind of catecholamine receptors found in the lungs, and not those in the heart.”

“The new drug is also more selective for a similar receptor found in muscle and fat. In theory at least, it should have beneficial metabolic effects – like the older class of medication – without affecting the heart.”

Lee sourced the drug in its oral form, found the dose needed to give a metabolic effect, and gave it to 8 healthy men over a week.

“Energy metabolism increased by more than 10%, fat burning increased by more than 25%, while protein burning fell by 15%,” he said.

“So although whole body metabolism increased, these men burned fat while reducing the burning of protein. That’s a good thing because in the long run these effects may lead to a loss in fat mass and an increase in muscle.

“In this study, all 8 subjects tolerated the medication well – without any significant increase in heart rate.”

The next step will be to test the drug over a longer period in a larger sample of people to determine if the beneficial effects translate into improvement in body composition, health and function.

Energy expenditure and fat burning were calculated using ‘indirect calorimetry’ - a device that measures levels of oxygen inhaled and carbon dioxide exhaled.

Protein metabolism was measured using the state-of-the art method known as 'leucine turnover technique'. The amino acid leucine was infused and its fate tracked throughout the body to estimate rate of protein synthesis and breakdown.

ABOUT GARVAN

The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent's Hospital in Sydney, it is now one of Australia's largest medical research institutions with over 500 scientists, students and support staff. Garvan's main research programs are: Cancer, Diabetes & Obesity, Immunology and Inflammation and Neuroscience. Garvan's mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan's discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.



Read at BioSpace.com

   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES